Riesgos, prevención, diagnóstico | 23 JUL 21

Cáncer de esófago

Conceptos actuales sobre el adenocarcinoma de esófago y de la unión gastroesofágica. Diagnóstico precoz, riesgos y estrategias preventivas actuales
Autor/a: Sri G Thrumurthy, M Asif Chaudry , Sasha S D Thrumurthy, Muntzer Mughal BMJ 2019;366:l4373
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.10.3322/caac.21492 30207593

2 Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009;3(Suppl):S2-5.19461918

3 Hur C, Miller M, Kong CY, etal . Trends in esophageal adenocarcinoma incidence and  mortality. Cancer 2013;119:1149-58. 10.1002/cncr.27834. 23303625

4 AminMB, EdgeS, GreeneF, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing, 2017. https://www.springer.com/gb/book/9783319406176

5 Shaheen NJ, Falk GW, Iyer PG, Gerson LBAmerican College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol2016;111:30-50, quiz 51.10.1038/ajg.2015.322 26526079

6 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NICE guideline 12). 2015. https://www.nice.org.uk/guidance/ng12.

7 Visser E, Leeftink AG, van Rossum PSN, Siesling S, van Hillegersberg R, Ruurda JP. Waiting time from diagnosis to treatment has no impact on survival in patients with esophageal cancer. Ann Surg Oncol 2016;23:2679-89.10.1245/s10434-016-5191-6. 27012988

8 Healthcare Quality Improvement Partnership. National oesophago-gastric cancer Audit 2018. https://www.nogca.org.uk/content/uploads/2018/09/NOGCA-2018-Annual-Report-1.pdf#page=33.

9 Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam Physician 2017;95:22-8.28075104

10 Mayo Clinic. Esophageal cancer. https://www.mayoclinic.org/diseases-conditions/esophageal-cancer/symptoms-causes/syc-20356084.

11 Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.10.1093/ije/29.4.645 10922340

12 Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. SeminRadiat Oncol 2007;17:2-9.10.1016/j.semradonc.2006.09.003 17185192

13 Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.10.1093/jnci/djn211 18695138

14 Cancer Research UK. Oesophageal cancer incidence statistics: Oesophageal cancer incidence by age. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence#heading-One

15 National Cancer Institute. SEER cancer statistics review, 1975-2015. 2018. https://seer. cancer.gov/archive/csr/1975_2015/.

16 Cancer Research UK. Oesophageal cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence#heading-One.

17 Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.10.1056/NEJM199903183401101 10080844

18 Hvid-Jensen F, Pedersen L, Drewes AMAM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375-83.10.1056/NEJMoa1103042 21995385

19 Schulmann K, Sterian A, Berki A, etal . Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-48.10.1038/sj.onc.1208598 15824739

20 Fitzgerald RC, di Pietro M, Ragunath K, etal. British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014;63:7-42.10.1136/gutjnl-2013-305372 24165758

21 Sikkema M, de Jonge PJF, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44, quiz e32.10.1016/j.cgh.2009.10.010 19850156

22 Weusten B, Bisschops R, Coron E, etal . Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017;49:191-8.10.1055/s-0042-122140 28122386

23 Merry AHH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007;56:1503-11.10.1136/gut.2006.116665 17337464

24 Chow WH, Blot WJ, Vaughan TL, etal . Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.10.1093/jnci/90.2.150 9450576

25 Locke GR3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9.10.1016/S0002-9343(99)00121-7 10378622

26 Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.10.7326/0003-4819-130-11-199906010-00003 10375336

27 Devesa SS, Blot WJ, Fraumeni JFJr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2 9827707

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024